Přejít k hlavnímu obsahu

Ondra Martin M.Sc.

Journals

ONDRA, M., L. LENART, A. CENTORAME, D. DUMUT, A. HE, S. ZAIDI, J. HANRAHAN, J. DE SANCTIS, D. RADZIOCH, M. HAJDÚCH
CRISPR/Cas9 bioluminescence-based assay for monitoring CFTR trafficking to the plasma membrane. Life Science Alliance. 2023, 7(1), e202302045, ISSN: 2575-1077, PMID: 37918963,
KUBÍČKOVÁ, A., Z. MACEČKOVÁ, P. VOJTA, M. ONDRA, J. VOLEJNÍKOVÁ, P. KOŘALKOVÁ, A. JUNGOVA, O. JAHODA, R. MOJZIKOVA, I. HADAČOVÁ, J. CERMAK, M. HORVÁTHOVÁ, D. POSPÍŠILOVÁ, M. HAJDÚCH
Missense mutation in RPS7 causes Diamond-Blackfan anemia via alteration of erythrocyte metabolism, protein translation and induction of ribosomal stress. Blood Cells, Molecules & Diseases. 2022, 97, 102690, ISSN: 1079-9796, PMID: 35871033,
CENTORAME, A., D. DUMUT, M. YOUSSEF, M. ONDRA, I. KIANICKA, J. SHAH, R. PAUN, T. OŽDIAN, J. HANRAHAN, E. GUSEV, B. PETROF, M. HAJDÚCH, R. PISLARIU, J. DE SANCTIS, D. RADZIOCH
Treatment With LAU-7b Complements CFTR Modulator Therapy by Improving Lung Physiology and Normalizing Lipid Imbalance Associated With CF Lung Disease. Frontiers inPharmacology. 2022, 13, 876842, ISSN: 1664-3224,  PDF.

Books & book chapters

Transformation of bacteria by PCR , 1.vyd., Olomouc, Palacky University, 2021, 7, 51-56, Dedication: LO1304, ISBN: 978-80-244-6049-9,

Intellectual property

SURFACE MODIFIED PARTICLES (Cígler)
  1. Patent: CZ 309422; Granted: 28.12.2022; Ownership: Institute of Organic Chemistry and Biochemistry CAS, Palacky University Olomouc; Inventors: Hajdúch MariánJaworek HanaOndra MartinKubíčková Agáta 
  2. Published Application PCT/CZ2021/050103 under WO 2022/068982 (7.4.2022)

Status: Available

SURFACE MODIFIED PARTICLES (Cígler)

Utility Model: CZ 34808; Granted: 10.2.2021; Ownership: Institute of Organic Chemistry and Biochemistry CAS, Palacky University Olomouc; Inventors: Hajdúch Marián, Jaworek Hana, Ondra Martin, Kubíčková Agáta

Status: Available

Master mentorship

Lenart Lukáš M.Sc.

CRISPR/Cas9 as a tool for the development of a cystic fibrosis model for high throughput screening of compounds

Stav: Absolvoval od 2021 do 2023.